Incidence of Subclinical and Clinical Acute Kidney Injury by a Novel Kidney Injury Biomarker, urine Neutrophil Gelatinase associated Lipocalin in Multidrug Resistant Septic Patients Treated with Colistimethate Sodium

Not Applicable

Recruiting

• Conditions: Early detection; Colistimethate Sodium; Acute kidney injury; Urine neutrophil gelatinase associated lipocalin; Cut off level

• Registration Number: TCTR20170330003
• Lead Sponsor: Ratchadaphiseksomphot Endowment Fund

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-03-30
• Study Completion: 2017-04-05
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

All patients over 18 years of age undergoing CMS treatment for more than 72 hours, eGFR ≥ 30 ml/min/1.73 m2 and hemodynamic stability

Exclusion Criteria

CKD stage G4 and G5, ESRD on renal replacement therapy, AKI that required hemodialysis within 24 hours after CMS was prescribed and pregnant patients

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of clinical AKI in septic patients after CMS use 26 months serum creatinine

Secondary Outcome Measures

Name	Time	Method
Incidence of subclinical AKI in septic patients after CMS use 26 months uNGA